CPC C12N 9/12 (2013.01) [A61K 38/45 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61K 47/64 (2017.08); C07K 14/71 (2013.01); C07K 16/00 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/70 (2013.01); C12N 2710/10043 (2013.01); C12Y 207/10001 (2013.01)] | 19 Claims |
1. A method of treating a subject having an ocular disorder associated with neovascularization, vascular endothelial cell proliferation, vascular permeability, edema or inflammation, the method comprising
administering to the subject a composition comprising:
(i) a soluble, ligand binding molecule comprising a ligand binding polypeptide, wherein the ligand binding polypeptide comprises an amino acid sequence having at least 95% identity to the sequence of amino acids defined by positions 47-115 of SEQ ID NO: 2, with the proviso that positions of the polypeptide corresponding to positions 104-106 of SEQ ID NO: 2 are not identical to N-X-S or N-X-T, and wherein the ligand binding polypeptide and the ligand binding molecule bind to at least one ligand polypeptide selected from human VEGF-C, VEGF-D, and PIGF; and
(ii) a pharmaceutically acceptable diluent, adjuvant, excipient, or carrier;
the method comprising administering to the subject the composition in an amount effective to inhibit neovascularization, vascular endothelial cell proliferation, vascular permeability, edema, or inflammation in the subject.
|